BNO 5.26% 20.0¢ bionomics limited

BNC210 coverage on Channel 9, page-22

  1. 707 Posts.
    lightbulb Created with Sketch. 78
    Oh dear, we seem to have a one track mind.

    Clinical results and that is all there is?

    Sorry, but running out of cash matters.

    Sorry, ongoing selling by a major shareholder tells us something too.

    After all the lead up and the big valuations - based on a whole bunch of assumptions about pricing, timing, market penetration etc - and all assuming that BNC 210 is a blockbuster.

    That my friend is heroic.

    Best of luck and I hope to goodness you have not bet the house on this one.

    There are multiple issues facing this company and the clinical trial results are important but they are not the only factor in the valuation or the share price.

    Good luck Champ.
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.